Alibaba Agrees to $600 Million U.S. Settlement Over Illegal Pharmaceutical Sales Allegations

BY EMMANUEL OGBONNA 

Chinese technology giant Alibaba has agreed to pay $600 million to resolve a long-running investigation by the U.S. government into allegations that illegal pharmaceuticals, controlled substances, regulated chemicals, and pill-making equipment were sold and imported into the United States through its online marketplaces.

The settlement brings to a close a federal investigation into the company’s role in facilitating the sale of prohibited products on its global e-commerce platforms, including Alibaba.com and AliExpress. U.S. authorities alleged that Alibaba failed to implement adequate safeguards to prevent merchants from offering products that violated American laws governing pharmaceuticals, medical products, and controlled substances.

According to the agreement reached with the U.S. Department of Justice, Alibaba acknowledged that between January 2016 and December 2024 it failed to stop approximately 80,000 sales involving products that were unlawfully imported into the United States. Authorities said those transactions violated the Federal Food, Drug, and Cosmetic Act as well as several other federal laws designed to regulate the importation and sale of restricted products.

Federal investigators alleged that Alibaba’s U.S.-based payment processor, AUS Merchant Services, did not take sufficient steps to prevent third-party merchants from using the company’s online platforms to sell illegal goods to American customers. Prosecutors argued that the payment system processed transactions that should have been identified and blocked under U.S. regulations.

The investigation also found that Alibaba employees had internally raised concerns about weaknesses in the company’s compliance systems. According to government officials, those concerns highlighted shortcomings in monitoring mechanisms that allowed prohibited products to remain available for purchase by U.S. consumers.

Authorities further alleged that some merchants used Alibaba’s internal messaging services to communicate with customers before directing them to third-party messaging applications, where they continued discussions related to the sale and shipment of restricted products. Investigators said these practices made it more difficult to detect unlawful transactions and enforce platform policies.

As part of the investigation, law enforcement agencies carried out more than 40 undercover purchases involving pharmaceuticals, chemical substances, and equipment that are illegal to import into the United States. The operation involved investigators from multiple federal agencies, including the U.S. Food and Drug Administration, the Federal Deposit Insurance Corporation, the Internal Revenue Service Criminal Investigation division, and other government partners.

Rather than pursuing criminal charges, the Justice Department entered into a non-prosecution agreement with Alibaba. Under the agreement, the company will pay the $600 million settlement and continue strengthening its compliance programs, internal monitoring systems, and oversight of third-party merchants selling products to U.S. customers.

Alibaba said in a statement that it had reached a mutually satisfactory resolution with the U.S. government. The company stated that the agreement reflects its commitment to enhancing compliance measures governing products sold by third-party merchants on its e-commerce platforms in the United States. Alibaba added that it will continue working to strengthen its safeguards and ensure merchants comply with applicable laws and regulations.

The settlement represents one of the largest enforcement actions involving an international e-commerce platform accused of facilitating illegal cross-border sales. It also underscores increasing scrutiny by U.S. regulators over online marketplaces that connect overseas sellers with American consumers.

Federal officials said the case demonstrates the importance of holding companies accountable when compliance failures allow unlawful products to enter the U.S. marketplace. Investigators emphasized that online platforms handling international commerce are expected to maintain effective systems capable of identifying, preventing, and reporting illegal activity.

IRS Criminal Investigation Chief Jarod Koopman said the resolution reinforces the agency’s commitment to tracking financial transactions connected to unlawful activity and ensuring that companies operating within the United States fully comply with federal law. He added that authorities will continue pursuing cases involving businesses that fail to prevent illegal commerce through their platforms.

The agreement concludes years of investigation while requiring Alibaba to strengthen oversight of its global marketplace operations and improve protections aimed at preventing illegal products from reaching U.S. consumers.

Original article: https://yournews.com/2026/07/01/7091316/alibaba-agrees-to-600-million-u-s-settlement-over-illegal-pharmaceutical/